Savara's Q1 Net Loss Widens to $37.28M on Increased R&D for Key Drug
SVRA has more than doubled off its 52-week low of $1.89.
Summary
Savara Inc. reported a Q1 net loss of $37.28 million, which widened year-over-year, primarily driven by increased research and development (R&D) and administrative expenses. This higher spending is largely attributed to the MOLBREEVI program, including manufacturing and personnel costs, as the company prepares for its potential commercial launch. This earnings report follows the company's recent 10-K filing, which highlighted the FDA granting Priority Review for MOLBREEVI. While the widening loss is a negative financial outcome, the company ended the quarter with $203 million in cash, stating it is well-capitalized for the anticipated drug launch. Traders will be focused on the upcoming FDA decision for MOLBREEVI, expected by November 22, 2026, as a key catalyst.
At the time of this announcement, SVRA was trading at $5.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.89 to $7.01. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.